TABLE 2

Wilson’s criteria for an ideal screening test, applied to cardiac surveillance for chemotherapy

Criteria24Surveillance echocardiography for chemotherapy
The condition should be an important health problemCardiotoxicity is an important health problem but is detectable by screening only in a minority of patients
The natural history of the condition should be understoodThe natural history of cardiotoxicity has been reasonably well studied for established chemotherapy agents such as anti-HER2
There should be a recognizable latent or early symptomatic stageLeft ventricular dysfunction typically relates to acute toxicity and becomes manifest within the first year of exposure. Early recognition is important, because cumulative doses typically compound toxicity
A test should exist that is easy to perform and interpret, and is acceptable, accurate, reliable, sensitive, and specificImaging with echocardiography has these qualities but also involves considerable challenges and limitations
An accepted treatment for the disease should existCurrent guideline-directed heart failure management is recognized as treatment for chemotherapy-related cardiomyopathy. Evidence is limited for specific treatments beyond these guidelines, although the subject is under active investigation
Treatment should be more effective if started earlyIf started early, current guideline-directed heart failure management is considered to be more effective. Early recognition of chemotherapy-related cardiomyopathy is important for preventing additional dose exposures, which typically compound toxicity
There should be a policy on who should be treatedCurrent guideline-directed heart failure management covers who should be treated
Diagnosis and treatment should be cost-effectiveLimited data suggest favorable cost-effectiveness for screening and early treatment, although a more targeted approach can likely significantly improve it
Case-finding should be a continuous processCase-finding can be a continuous process